Osteoarthritis Pathophysiology

Osteoarthritis is a whole joint disease involving cartilage degradation, subchondral bone remodeling, osteophyte formation, synovial inflammation, and soft tissue changes—not simply "wear and tear" of cartilage. The fundamental pathology is an imbalance where catabolic pathways exceed anabolic capacity 3-5 times, driven by master inflammatory mediators IL-1β and TNF-α that upregulate destructive enzymes: MMP-13 (primary collagenase) and ADAMTS-4/5 (aggrecanases). Subchondral bone undergoes sclerosis with 40% volume increase, cyst formation, and bone marrow lesions (BMLs) that correlate with pain—these changes may precede or follow cartilage loss. Early OA shows paradoxically increased cartilage water content from proteoglycan loss, while senescent cells accumulate with pro-inflammatory SASP phenotype, driving progression even in the absence of acute inflammation. Currently, no disease-modifying OA drugs (DMOADs) have been approved.

Osteoarthritis (OA) was historically viewed as simple "wear and tear" of cartilage. The modern understanding recognizes OA as a complex, multifactorial disease of the entire joint organ, involving all tissues and driven by biomechanical and inflammatory mechanisms.

The paradigm shift from passive degeneration to active disease process emphasizes failed repair responses, where chondrocytes attempt regeneration but produce inferior matrix. This understanding has opened therapeutic avenues targeting inflammation, senescence, and metabolic pathways.

Core Pathophysiological Concepts

Central Paradigm: Failed Repair Response

OA represents a fundamental failure of joint homeostasis where catabolic processes overwhelm anabolic repair mechanisms. This creates a self-perpetuating cycle of degradation.

Key Molecular Imbalance:

• Catabolic mediators: IL-1beta, TNF-alpha, MMPs, ADAMTS
• Anabolic mediators: IGF-1, TGF-beta, BMPs
• Net result: 3-5x more degradation than synthesis

Tissue Crosstalk:

The whole joint disease concept emphasizes bidirectional communication between tissues:

• Cartilage degradation products activate synovial inflammation
• Synovial cytokines accelerate cartilage catabolism
• Subchondral bone changes alter mechanical loading on cartilage
• Osteophytes form as attempted stabilization

Early Changes

OA cartilage undergoes progressive structural and compositional changes beginning at molecular level before gross damage appears.

Compositional Changes:

• Water content: Increases from 70% to 80%+ (proteoglycan loss)
• Collagen content: Net loss despite repair attempts
• Collagen crosslinking: Altered (more immature crosslinks)
• Matrix organization: Disrupted fibrillar architecture

Catabolic Enzymes

Matrix degradation is mediated by specific proteases that are upregulated in OA chondrocytes.

IL-1beta Signaling Cascade:

1. IL-1beta binds IL-1R1 receptor
2. Recruits IL-1RAcP co-receptor
3. Activates MyD88 adapter protein
4. Triggers NF-kappaB and MAPK (p38, ERK, JNK) pathways
5. Nuclear translocation of transcription factors
6. Upregulation of MMP-13, ADAMTS-4/5, iNOS, COX-2
7. Downregulation of collagen II, aggrecan synthesis

Chondrocyte Phenotypic Changes

OA chondrocytes undergo phenotypic alterations attempting to repair damaged matrix but ultimately contributing to pathology.

Cell Clusters:

• Chondrocyte proliferation near damaged areas
• Attempt to synthesize new matrix
• Produce inferior quality (more type I collagen)
• Short-lived response - cells eventually undergo apoptosis
• Sign of failed repair attempt

Hypertrophic Differentiation:

• Expression of type X collagen (normally only in growth plate)
• Upregulation of MMP-13, VEGF, RUNX2
• Promotes calcification and vascular invasion
• Recapitulates endochondral ossification program
• Contributes to osteophyte formation

Senescence:

• Accumulation of senescent cells with aging and OA
• Senescence-associated secretory phenotype (SASP)
• SASP includes IL-6, IL-8, MMPs, growth factors
• Drives chronic inflammation
• Target for senolytics (drugs clearing senescent cells)

Bone Remodeling

Subchondral bone undergoes dramatic changes in OA, with active remodeling that may precede or accelerate cartilage loss.

Early Bone Changes:

• Increased bone turnover markers (CTX-I, NTX-I)
• Trabecular thickening (40% volume increase)
• Altered bone mineralization density
• Microdamage and microcracks

Advanced Bone Changes:

• Sclerosis visible on radiographs
• Subchondral cysts (geodes)
• Bone marrow lesions on MRI
• Osteophyte formation at margins

Chicken or Egg Debate: Does subchondral bone pathology cause cartilage loss, or vice versa? Evidence suggests bidirectional relationship with both contributing to progression.

Bone Marrow Lesions (BMLs)

BMLs are areas of high signal intensity on T2-weighted or STIR MRI sequences, representing bone marrow edema, microfracture, ischemia, or necrosis.

Clinical Significance:

• Strong correlation with knee pain severity
• Predict risk of cartilage loss progression
• Fluctuate over time (unlike structural damage)
• May respond to bone-targeted therapies

Treatment Implications:

• Bisphosphonates may reduce BML size and pain
• Unloading (e.g., valgus brace for medial BMLs) may help
• Targeting bone may be as important as targeting cartilage

Low-Grade Synovitis

OA synovium exhibits chronic low-grade inflammation distinct from rheumatoid arthritis but still contributing to symptoms and progression.

Inflammatory Features:

• Synovial hyperplasia (2-3x normal thickness)
• Infiltration of macrophages and lymphocytes
• Increased vascularity
• Elevated inflammatory mediators (IL-1, TNF, IL-6)

Synovial Membrane Changes:

• Lining layer hyperplasia (normally 1-2 cells thick, becomes 4-10)
• Sublining fibrosis and inflammation
• Release of matrix fragments (wear particles)
• Activation of complement cascade

Inflammatory Mediators Released:

• Cytokines: IL-1beta, TNF-alpha, IL-6, IL-8
• Chemokines: MCP-1, RANTES
• Growth factors: VEGF, NGF (nerve growth factor)
• Enzymes: MMPs, ADAMTS, hyaluronidase

Complement Activation

The complement system, classically associated with immune responses, is activated in OA synovium and contributes to tissue damage.

Activation Pathways:

• Alternative pathway triggered by cartilage degradation products
• C5a and membrane attack complex (MAC) formation
• Amplifies inflammatory response
• Contributes to synovial and cartilage damage

Therapeutic Target: Complement inhibitors are being investigated as potential DMOADs.

Distinguishing OA from inflammatory and crystal arthropathies is a recurring viva and MCQ theme. OA is a non-inflammatory, mechanically driven, low-grade-inflammatory disease, contrasted with the immune-mediated and crystal-driven processes below.

OA pathophysiology remains an active research field with several unresolved debates that examiners use to test depth of understanding.

Current Therapeutic Landscape

No disease-modifying OA drugs (DMOADs) have been approved despite extensive research. Current treatments are symptomatic.

Symptomatic Treatments:

• NSAIDs: COX-2 inhibition reduces pain, doesn't slow progression
• Viscosupplementation: Hyaluronic acid - modest short-term benefit
• Corticosteroid injection: Anti-inflammatory, temporary relief
• Analgesics: Acetaminophen, tramadol for pain

Investigational DMOADs:

• Anti-NGF antibodies: Reduced pain but safety concerns (joint damage, fractures)
• FGF-18 (sprifermin): Early promise for cartilage regeneration
• Wnt pathway inhibitors: Target aberrant signaling
• Senolytics: Clear senescent cells

Emerging Concepts

Metabolic OA: Recognition that obesity contributes via metabolic mechanisms (adipokines, inflammation) not just mechanical overload. Leptin, adiponectin, resistin from adipose tissue promote OA.

Genetic Factors: GWAS studies identify OA susceptibility loci (GDF5, COL11A1, SMAD3). Genetic risk scores may predict progression and guide personalized therapies.

Microbiome: Emerging evidence that gut microbiome influences OA via systemic inflammation. Dysbiosis may contribute to disease.

Global Epidemiology

• OA is the most common joint disease worldwide and a leading global cause of years lived with disability; the knee is the most affected large joint.
• Prevalence rises steeply with age and is higher in women, particularly after menopause; obesity is the strongest modifiable risk factor.
• OA is the dominant indication for hip and knee arthroplasty across major joint registries (NJR, AJRR, AOANJRR, SHAR, NZJR), accounting for the large majority of primary procedures.
• Burden is rising globally with population ageing and rising obesity, with growing impact in low- and middle-income countries.

Guidelines Compared (Management Principles)

There is broad international agreement that core non-pharmacological treatment (exercise, weight loss, education) precedes drugs, that no pharmacological agent is disease-modifying, and that arthroscopic lavage/debridement is not recommended for OA. Divergence is mainly over hyaluronic acid (against in NICE/AAOS) and the weight given to intra-articular corticosteroid.

Registry & Research Notes

• Joint registries confirm OA as the overwhelming primary indication for arthroplasty and provide long-term implant survival data informing end-stage decision-making.
• DMOAD development is global: ADAMTS-5/aggrecanase inhibitors, FGF-18 (sprifermin), Wnt inhibitors and senolytics are in trials across multiple regions, but none is approved.

High- vs Limited-Resource Practice Variation

• High-resource settings: ready access to MRI phenotyping, intra-articular therapies, and timely arthroplasty for end-stage disease.
• Limited-resource settings: emphasis on low-cost high-value interventions (structured exercise, weight loss, simple analgesia); imaging often limited to plain radiographs, and arthroplasty access may be constrained—making conservative, non-operative optimisation especially important.